Good afternoon, everyone and thank you for joining our conference call to discuss BioStem Technologies' first quarter 2025 financial results and corporate highlights. Leading the call today will be ...

RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 Pivotal trial more than half enrolled, with completion expected in 2025 Additional ...

Operator: Good day, ladies and gentlemen. Welcome to Assertio Holdings First Quarter 2025 Results Conference Call. Just a ...

Anthony Edwards scored 30 points for his second straight 30-point performance, Julius Randle had 31 points and the Minnesota ...

Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additi ...

To avoid being charged the recurring subscription fee, simply cancel before the free-trial period ends - it’s just $4.99/mo afterward. *To avoid being charged the recurring subscription fee ...

Total Liabilities Shareholders' Equity 4,80,196.57 4,47,913.25 4,24,945.90 3,98,887.64 ...